z-logo
open-access-imgOpen Access
Oroxylin A attenuates cytokines in neonatal asthmatic mice by regulating Notch signaling pathway
Author(s) -
Peng Hua,
Wei Wang,
LiNa Xiao,
H. J. Tao
Publication year - 2022
Publication title -
tropical journal of pharmaceutical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.209
H-Index - 36
eISSN - 1596-5996
pISSN - 1596-9827
DOI - 10.4314/tjpr.v20i6.7
Subject(s) - ovalbumin , pharmacology , notch signaling pathway , medicine , protein kinase b , pi3k/akt/mtor pathway , western blot , proinflammatory cytokine , notch 1 , immunology , signal transduction , chemistry , inflammation , immune system , receptor , biochemistry , gene
Purpose: To investigate the protective effect of oroxylin A against neonatal asthma in mice. Methods: Asthma was induced in P12 mice with ovalbumin (OVA) immediately after litter (day 0), and on day 14 of protocol. Oroxylin A was given daily in two doses (2 and 10 mg/kg, i.p.) from day 0 to 14, 2 h before the administration of OVA. The protective effect of oroxylin A against asthma was determined by evaluating lung function and levels of cytokines and IgE in OVA-challenged mice. Moreover, Western blot assay and quantitative real-time polymerase chain reaction (qRT-PCR) were used to determine the effect of oroxylin A on Notch signaling pathway in OVA-challenged mice. Results: Oroxylin A improved lung function in OVA-challenged mice. There were significant (p < 0.01) reductions in levels of IgE and cytokines in the BALF of oroxylin A-treated group, when compared to OVA group of mice. Furthermore, treatment with oroxylin A significantly ameliorated the OVA-induced changes in protein expressions of Notch1, Jagged1, NICD, PTEN, PI3K and Akt in the CD+ cells of OVA-challenged mice (p < 0.01). Conclusion: These results indicate that oroxylin A improves lung function and reduces the level of cytokines in neonatal asthmatic rat by downregulating Notch signaling. Thus, oroxylin A may be clinically beneficial in the management of asthma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here